Back to MYL Stock Lookup

MYL Related Analyst Ratings

May 20, 2013 11:43 AM UPDATE: Lazard Capital Downgrades Warner Chilcott (WCRX), Says Deal Could Fall Through

May 10, 2013 06:38 AM BMO Capital Starts Mylan (MYL) at Underperform

May 9, 2013 05:38 PM Janney Montgomery Scott Starts Mylan (MYL) at Buy

May 3, 2013 12:21 PM Mylan (MYL) Still a Strong Buy at Needham & Company

Mar 25, 2013 06:46 AM Bernstein Downgrades Mylan (MYL) to Market Perform

Mar 11, 2013 08:07 AM Canaccord Genuity Downgrades Mylan (MYL) to Hold

Feb 28, 2013 10:18 AM UBS Bumps PT on Mylan (MYL) to $33; Agila Deal a Good Way to Start 2013

Jan 8, 2013 06:45 AM Morgan Stanley Downgrades Mylan (MYL) to Equalweight

Nov 28, 2012 09:03 AM Canaccord Genuity Boosts Target on Mylan (MYL), Answers 5 Key Questions

Nov 16, 2012 10:02 AM Leerink Swann Upgrades Mylan (MYL) to Outperform

Oct 26, 2012 09:14 AM Canaccord Genuity Upgrades Mylan (MYL) to Buy; Set to Break-Out

Sep 18, 2012 08:34 AM Guggenheim Starts Mylan (MYL) at Neutral

Sep 10, 2012 08:59 AM Canaccord Genuity Maintains a 'Hold' on Mylan (MYL); Thesis Becoming More Positive

Sep 10, 2012 08:49 AM Needham & Company Maintains a 'Buy' on Warner Chilcott (WCRX); Loses Appeal

Sep 10, 2012 08:43 AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Detrol LA Settlement Provides Small Dose of Certainty

Aug 24, 2012 08:05 AM Needham & Company Maintains a 'Hold' on Par Pharmaceutical (PRX); Is Endo (ENDP) the 'Mystery Bidder'

Aug 24, 2012 07:59 AM Needham & Company on Endo Pharmaceuticals (ENDP): Watson (WPI) Gains First Generic Lidoderm Approval; A Few Other Issues Too

Jul 31, 2012 02:05 PM UBS Maintains a 'Buy' on Mylan (MYL); Don't Underestimate the EpiPen

Jul 27, 2012 02:47 PM Canaccord Genuity Maintains a 'Hold' on Mylan (MYL); Raising PT on Solid Q2

Jul 27, 2012 10:51 AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Continuing to Grind Out Upside

Jul 24, 2012 04:52 PM Barclays Maintains an 'Overweight' on Mylan (MYL); Q2 Preview: Expected Mixed Results

Jul 20, 2012 08:31 AM Needham & Company maintains a 'Strong Buy' on Mylan (MYL); PRX Grossly Undervalued by TGP, MYL/PRX Instead As Strong Combo

Jul 16, 2012 02:39 PM Leerink Swann Downgrades Par Pharmaceutical (PRX) to Market Perform; Not Expecting Mylan (MYL) To Up The Ante

Jul 3, 2012 01:18 PM UBS Q2 Preview on U.S. Pharmaceuticals: Safe Havens in Generic, Specialty and Large-Cap

Jun 26, 2012 11:05 AM UBS Defends Momenta Pharmaceuticals (NASDAQ: MNTA); Negative News Largely In Stock

Jun 26, 2012 07:40 AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Brushing Off Generic Copaxone Loss

Jun 25, 2012 12:46 PM UBS Maintains a 'Buy' on Teva Pharma (TEVA); The Decision's In

Jun 25, 2012 09:01 AM Canaccord Genuity Reiterates a 'Buy' on Teva Pharma (TEVA); Win Now A Reality

Jun 19, 2012 03:48 PM Barclays on U.S. Specialty Pharmaceuticals: Muddling Now, but Opportunity Remains

Jun 19, 2012 07:12 AM Goldman Sachs Adds Watson Pharmaceuticals (WPI) to Conviction Buy List, Cheap Vs. Peers

May 21, 2012 10:05 AM Canaccord Genuity on Pharmaceuticals: Generic Valuation at Historical Trough Level Ahead of Meetings

May 11, 2012 12:37 PM Goldman Sachs Sees Mylan (MYL) as a Strong Takeover Target

May 10, 2012 11:11 AM Canaccord Genuity on Specialty Pharma: TEVA's Q1 Effect on Specialty Pharma (TEVA, WPI, PRGO & MYL)

May 1, 2012 08:26 AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Chalk One Up in the PIV Win Column As Doryx Goes Generic

Apr 26, 2012 10:42 AM UPDATE - Auriga Initiates Coverage on Forest Laboratories (FRX); Lack of Near Term Catalysts Keep Us Sidelined

Apr 10, 2012 01:26 PM UBS on U.S. Pharma - Large Cap and Specialty: Q1 Preview - Off to a Good Start

Apr 9, 2012 02:10 PM Barclays on U.S. Specialty Pharmaceuticals: Model Adjustments on MYL, PRX, TEVA, & WCRX

Apr 9, 2012 09:59 AM Canaccord Genuity on Life Sciences/Specialty Pharmaceuticals Modafinil Decision Adds EPS Headwind to MYL, Benefit to TEVA

Apr 4, 2012 11:23 AM Canaccord Genuity on Life Sciences/Specialty Pharma: What an Actavis Deal Could Mean to Watson (WPI) and the Sector

Mar 15, 2012 08:28 AM Susquehanna Starts Mylan (MYL), Watson (WPI) at Positive, Teva (TEVA) at Neutral

Mar 7, 2012 02:07 PM Barclays Maintains an 'Overweight' on Mylan (MYL); EpiPen: Overcoming a Wall of Worry

Feb 22, 2012 10:08 AM Canaccord Genuity Maintains a 'Hold' on Mylan (MYL); Analyst Day Big on Detail, Small on Guidance Surprise

Feb 14, 2012 07:17 AM Goldman Sachs Upgrades Mylan (MYL) to Buy, Sees Earnings Revised Higher

Feb 6, 2012 09:29 AM Canaccord Genuity on Life Sciences/Specialty Pharmaceuticals: Q4/11 Preview: Post-2012 Message a Growing Focus: WPI and IPXL Top Ideas

Feb 6, 2012 08:22 AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL)l Mid-May Is D-Day for Generic Lidoderm, Not July

Jan 12, 2012 01:55 PM UBS on U.S. Pharma – Large Cap and Specialty: 4Q11 Preview: Things Still Look Interesting

Dec 20, 2011 08:01 AM Needham & Company: Specialty Pharmaceuticals - 2012 Preview: European Hangover Expected to Ease; Valuations Reflect Fear Not Fact

Dec 13, 2011 11:39 AM Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings

Dec 9, 2011 01:15 PM Barclays Initiating Coverage: A Seamless Approach to Biopharmaceuticals

Dec 8, 2011 11:12 AM Canaccord Genuity Generic Sector Revisit - Focus on Path Ahead of Several Near-term Catalysts

Back to MYL Stock Lookup